Patient‐reported outcomes and inflammatory biomarkers in patients with locally advanced/metastatic urothelial carcinoma treated with durvalumab in phase 1/2 dose‐escalation study 1108
Background Durvalumab has shown meaningful clinical activity in patients with metastatic urothelial carcinoma (mUC) in Study 1108 (NCT01693562). An important focus in treatment is health‐related quality of life (HRQOL). Here, patient‐reported outcomes (PROs) from Study 1108 and their relationship wi...
Gespeichert in:
| Veröffentlicht in: | Cancer 2020-01, Vol.126 (2), p.432-443 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 443 |
|---|---|
| container_issue | 2 |
| container_start_page | 432 |
| container_title | Cancer |
| container_volume | 126 |
| creator | O'Donnell, Peter H. Arkenau, Hendrick Tobias Sridhar, Srikala S. Ong, Michael Drakaki, Alexandra Spira, Alexander I. Zhang, Jingsong Gordon, Michael S. Degboe, Arnold N. Gupta, Ashok K. Mukhopadhyay, Pralay Huang, Wenmei Abdullah, Shaad E. Angra, Natasha Roskos, Lorin K. Guo, Xiang Friedlander, Terence |
| description | Background
Durvalumab has shown meaningful clinical activity in patients with metastatic urothelial carcinoma (mUC) in Study 1108 (NCT01693562). An important focus in treatment is health‐related quality of life (HRQOL). Here, patient‐reported outcomes (PROs) from Study 1108 and their relationship with inflammatory biomarkers are explored.
Methods
Disease‐related symptoms, functioning, and HRQOL were assessed with the Functional Assessment of Cancer Therapy–Bladder (FACT‐Bl) and the European Organisation for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire Core 30 (QLQ‐C30). Relationships between PRO improvements and the best changes in the tumor size, albumin level, and neutrophil‐lymphocyte ratio (NLR) were assessed with Spearman correlation analysis.
Results
The mean FACT‐Bl total score improved from 107.5 (standard deviation [SD], 23.0) at the baseline to 115.4 (SD, 22.6) on day 113, with similar increases found for the Trial Outcome Index (TOI) and Bladder Cancer Subscale (BLCS) scores. The mean FACT‐Bl total scores improved over time, and the FACT‐Bl TOI scores significantly improved by day 113 (P |
| doi_str_mv | 10.1002/cncr.32532 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_journals_2334698916</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2334698916</sourcerecordid><originalsourceid>FETCH-LOGICAL-c3932-553a40160be27d4e47a65a682526da8e2bbcafd4c21da6e08ce2fea15cf22b043</originalsourceid><addsrcrecordid>eNp9kc9q3DAQh0VJaTZpL32AIMit4F39sb3eY1iSJrC0pSTQmxlLY9aJbG0keRff8gh9n7xNnyTadZpjToOGb74Z9CPkK2dTzpiYqU65qRSZFB_IhLPFPGE8FUdkwhgrkiyVf47Jiff38TmP1CdyLHlWcMnyCXn-BaHBLvx7-utwY11ATW0flG3RU-g0bbraQNtCsG6gVWNbcA_ofOzTzTjq6a4Ja2qsAmMGCnoLnUI9azGAD5FRtHc2rNE0YKgCp5ouamhwCPt1h2nduy2YvoXqYF6DR8pngmrrMd6GPsqjynbUh14PlHNWfCYfazAev7zWU3J3dXm7vE5WP7_fLC9WiZILKZIsk5AynrMKxVynmM4hzyAvRCZyDQWKqlJQ61QJriFHVigUNQLPVC1ExVJ5Ss5H78bZxx59KO9t77q4shRSpvmiWPA8Ut9GSjnrvcO63Lgm_tZQclbucyr3OZWHnCJ89qrsqxb1G_o_mAjwEdg1Bod3VOXyx_L3KH0BhuCkZw</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2334698916</pqid></control><display><type>article</type><title>Patient‐reported outcomes and inflammatory biomarkers in patients with locally advanced/metastatic urothelial carcinoma treated with durvalumab in phase 1/2 dose‐escalation study 1108</title><source>Wiley-Blackwell Journals</source><source>Wiley Online Library Free Content</source><source>Free E-Journal (出版社公開部分のみ）</source><source>Alma/SFX Local Collection</source><creator>O'Donnell, Peter H. ; Arkenau, Hendrick Tobias ; Sridhar, Srikala S. ; Ong, Michael ; Drakaki, Alexandra ; Spira, Alexander I. ; Zhang, Jingsong ; Gordon, Michael S. ; Degboe, Arnold N. ; Gupta, Ashok K. ; Mukhopadhyay, Pralay ; Huang, Wenmei ; Abdullah, Shaad E. ; Angra, Natasha ; Roskos, Lorin K. ; Guo, Xiang ; Friedlander, Terence</creator><creatorcontrib>O'Donnell, Peter H. ; Arkenau, Hendrick Tobias ; Sridhar, Srikala S. ; Ong, Michael ; Drakaki, Alexandra ; Spira, Alexander I. ; Zhang, Jingsong ; Gordon, Michael S. ; Degboe, Arnold N. ; Gupta, Ashok K. ; Mukhopadhyay, Pralay ; Huang, Wenmei ; Abdullah, Shaad E. ; Angra, Natasha ; Roskos, Lorin K. ; Guo, Xiang ; Friedlander, Terence</creatorcontrib><description>Background
Durvalumab has shown meaningful clinical activity in patients with metastatic urothelial carcinoma (mUC) in Study 1108 (NCT01693562). An important focus in treatment is health‐related quality of life (HRQOL). Here, patient‐reported outcomes (PROs) from Study 1108 and their relationship with inflammatory biomarkers are explored.
Methods
Disease‐related symptoms, functioning, and HRQOL were assessed with the Functional Assessment of Cancer Therapy–Bladder (FACT‐Bl) and the European Organisation for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire Core 30 (QLQ‐C30). Relationships between PRO improvements and the best changes in the tumor size, albumin level, and neutrophil‐lymphocyte ratio (NLR) were assessed with Spearman correlation analysis.
Results
The mean FACT‐Bl total score improved from 107.5 (standard deviation [SD], 23.0) at the baseline to 115.4 (SD, 22.6) on day 113, with similar increases found for the Trial Outcome Index (TOI) and Bladder Cancer Subscale (BLCS) scores. The mean FACT‐Bl total scores improved over time, and the FACT‐Bl TOI scores significantly improved by day 113 (P < .05). The mean EORTC QLQ‐C30 Global Health Status/Quality of Life score improved from 57.1 (SD, 24.8) at the baseline to 69.0 (SD, 21.4) on day 113; the functional scale and symptom scores (day 113) were higher than the baseline scores (P < .05) for EORTC Social Functioning. The FACT‐Bl total, BLCS, and TOI scores improved in 32.6%, 34.9%, and 32.6% of the patients by day 113; 26.3% to 37.8% of the patients exhibited improvements in EORTC QLQ‐C30 functional scores. The best tumor shrinkage and posttreatment improvements in serum albumin and NLR correlated with increases in FACT‐Bl total, TOI, and BLCS scores and in EORTC Physical Functioning and Role Functioning scores (P < .05).
Conclusions
Durvalumab was associated with improvements in disease‐related symptoms, functioning, and HRQOL in patients with mUC. Improvements in systemic inflammation may contribute to PRO improvements in these patients.
In patients with locally advanced/metastatic urothelial carcinoma treated with durvalumab, improvements in patient‐reported outcomes correlate not only with objective tumor responses but also with reductions in markers of systemic inflammation. These findings provide insight into potential links between attenuation of inflammation in cancer and patient‐reported outcomes.</description><identifier>ISSN: 0008-543X</identifier><identifier>EISSN: 1097-0142</identifier><identifier>DOI: 10.1002/cncr.32532</identifier><identifier>PMID: 31581306</identifier><language>eng</language><publisher>United States: Wiley Subscription Services, Inc</publisher><subject>Albumin ; Biomarkers ; Bladder ; Bladder cancer ; Cancer ; Correlation analysis ; durvalumab ; Global health ; health‐related quality of life ; Immunotherapy ; Inflammation ; Lymphocytes ; Metastases ; Metastasis ; Monoclonal antibodies ; Oncology ; Patients ; patient‐reported outcome measures ; Quality of life ; Serum albumin ; Shrinkage ; Signs and symptoms ; Targeted cancer therapy ; tumor ; Tumors ; Urothelial carcinoma</subject><ispartof>Cancer, 2020-01, Vol.126 (2), p.432-443</ispartof><rights>2019 American Cancer Society</rights><rights>2019 American Cancer Society.</rights><rights>2020 American Cancer Society</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c3932-553a40160be27d4e47a65a682526da8e2bbcafd4c21da6e08ce2fea15cf22b043</citedby><cites>FETCH-LOGICAL-c3932-553a40160be27d4e47a65a682526da8e2bbcafd4c21da6e08ce2fea15cf22b043</cites><orcidid>0000-0003-2650-0049</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://onlinelibrary.wiley.com/doi/pdf/10.1002%2Fcncr.32532$$EPDF$$P50$$Gwiley$$H</linktopdf><linktohtml>$$Uhttps://onlinelibrary.wiley.com/doi/full/10.1002%2Fcncr.32532$$EHTML$$P50$$Gwiley$$H</linktohtml><link.rule.ids>314,780,784,1416,1432,27922,27923,45572,45573,46407,46831</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/31581306$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>O'Donnell, Peter H.</creatorcontrib><creatorcontrib>Arkenau, Hendrick Tobias</creatorcontrib><creatorcontrib>Sridhar, Srikala S.</creatorcontrib><creatorcontrib>Ong, Michael</creatorcontrib><creatorcontrib>Drakaki, Alexandra</creatorcontrib><creatorcontrib>Spira, Alexander I.</creatorcontrib><creatorcontrib>Zhang, Jingsong</creatorcontrib><creatorcontrib>Gordon, Michael S.</creatorcontrib><creatorcontrib>Degboe, Arnold N.</creatorcontrib><creatorcontrib>Gupta, Ashok K.</creatorcontrib><creatorcontrib>Mukhopadhyay, Pralay</creatorcontrib><creatorcontrib>Huang, Wenmei</creatorcontrib><creatorcontrib>Abdullah, Shaad E.</creatorcontrib><creatorcontrib>Angra, Natasha</creatorcontrib><creatorcontrib>Roskos, Lorin K.</creatorcontrib><creatorcontrib>Guo, Xiang</creatorcontrib><creatorcontrib>Friedlander, Terence</creatorcontrib><title>Patient‐reported outcomes and inflammatory biomarkers in patients with locally advanced/metastatic urothelial carcinoma treated with durvalumab in phase 1/2 dose‐escalation study 1108</title><title>Cancer</title><addtitle>Cancer</addtitle><description>Background
Durvalumab has shown meaningful clinical activity in patients with metastatic urothelial carcinoma (mUC) in Study 1108 (NCT01693562). An important focus in treatment is health‐related quality of life (HRQOL). Here, patient‐reported outcomes (PROs) from Study 1108 and their relationship with inflammatory biomarkers are explored.
Methods
Disease‐related symptoms, functioning, and HRQOL were assessed with the Functional Assessment of Cancer Therapy–Bladder (FACT‐Bl) and the European Organisation for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire Core 30 (QLQ‐C30). Relationships between PRO improvements and the best changes in the tumor size, albumin level, and neutrophil‐lymphocyte ratio (NLR) were assessed with Spearman correlation analysis.
Results
The mean FACT‐Bl total score improved from 107.5 (standard deviation [SD], 23.0) at the baseline to 115.4 (SD, 22.6) on day 113, with similar increases found for the Trial Outcome Index (TOI) and Bladder Cancer Subscale (BLCS) scores. The mean FACT‐Bl total scores improved over time, and the FACT‐Bl TOI scores significantly improved by day 113 (P < .05). The mean EORTC QLQ‐C30 Global Health Status/Quality of Life score improved from 57.1 (SD, 24.8) at the baseline to 69.0 (SD, 21.4) on day 113; the functional scale and symptom scores (day 113) were higher than the baseline scores (P < .05) for EORTC Social Functioning. The FACT‐Bl total, BLCS, and TOI scores improved in 32.6%, 34.9%, and 32.6% of the patients by day 113; 26.3% to 37.8% of the patients exhibited improvements in EORTC QLQ‐C30 functional scores. The best tumor shrinkage and posttreatment improvements in serum albumin and NLR correlated with increases in FACT‐Bl total, TOI, and BLCS scores and in EORTC Physical Functioning and Role Functioning scores (P < .05).
Conclusions
Durvalumab was associated with improvements in disease‐related symptoms, functioning, and HRQOL in patients with mUC. Improvements in systemic inflammation may contribute to PRO improvements in these patients.
In patients with locally advanced/metastatic urothelial carcinoma treated with durvalumab, improvements in patient‐reported outcomes correlate not only with objective tumor responses but also with reductions in markers of systemic inflammation. These findings provide insight into potential links between attenuation of inflammation in cancer and patient‐reported outcomes.</description><subject>Albumin</subject><subject>Biomarkers</subject><subject>Bladder</subject><subject>Bladder cancer</subject><subject>Cancer</subject><subject>Correlation analysis</subject><subject>durvalumab</subject><subject>Global health</subject><subject>health‐related quality of life</subject><subject>Immunotherapy</subject><subject>Inflammation</subject><subject>Lymphocytes</subject><subject>Metastases</subject><subject>Metastasis</subject><subject>Monoclonal antibodies</subject><subject>Oncology</subject><subject>Patients</subject><subject>patient‐reported outcome measures</subject><subject>Quality of life</subject><subject>Serum albumin</subject><subject>Shrinkage</subject><subject>Signs and symptoms</subject><subject>Targeted cancer therapy</subject><subject>tumor</subject><subject>Tumors</subject><subject>Urothelial carcinoma</subject><issn>0008-543X</issn><issn>1097-0142</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2020</creationdate><recordtype>article</recordtype><recordid>eNp9kc9q3DAQh0VJaTZpL32AIMit4F39sb3eY1iSJrC0pSTQmxlLY9aJbG0keRff8gh9n7xNnyTadZpjToOGb74Z9CPkK2dTzpiYqU65qRSZFB_IhLPFPGE8FUdkwhgrkiyVf47Jiff38TmP1CdyLHlWcMnyCXn-BaHBLvx7-utwY11ATW0flG3RU-g0bbraQNtCsG6gVWNbcA_ofOzTzTjq6a4Ja2qsAmMGCnoLnUI9azGAD5FRtHc2rNE0YKgCp5ouamhwCPt1h2nduy2YvoXqYF6DR8pngmrrMd6GPsqjynbUh14PlHNWfCYfazAev7zWU3J3dXm7vE5WP7_fLC9WiZILKZIsk5AynrMKxVynmM4hzyAvRCZyDQWKqlJQ61QJriFHVigUNQLPVC1ExVJ5Ss5H78bZxx59KO9t77q4shRSpvmiWPA8Ut9GSjnrvcO63Lgm_tZQclbucyr3OZWHnCJ89qrsqxb1G_o_mAjwEdg1Bod3VOXyx_L3KH0BhuCkZw</recordid><startdate>20200115</startdate><enddate>20200115</enddate><creator>O'Donnell, Peter H.</creator><creator>Arkenau, Hendrick Tobias</creator><creator>Sridhar, Srikala S.</creator><creator>Ong, Michael</creator><creator>Drakaki, Alexandra</creator><creator>Spira, Alexander I.</creator><creator>Zhang, Jingsong</creator><creator>Gordon, Michael S.</creator><creator>Degboe, Arnold N.</creator><creator>Gupta, Ashok K.</creator><creator>Mukhopadhyay, Pralay</creator><creator>Huang, Wenmei</creator><creator>Abdullah, Shaad E.</creator><creator>Angra, Natasha</creator><creator>Roskos, Lorin K.</creator><creator>Guo, Xiang</creator><creator>Friedlander, Terence</creator><general>Wiley Subscription Services, Inc</general><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7TO</scope><scope>7U7</scope><scope>C1K</scope><scope>H94</scope><scope>K9.</scope><scope>NAPCQ</scope><orcidid>https://orcid.org/0000-0003-2650-0049</orcidid></search><sort><creationdate>20200115</creationdate><title>Patient‐reported outcomes and inflammatory biomarkers in patients with locally advanced/metastatic urothelial carcinoma treated with durvalumab in phase 1/2 dose‐escalation study 1108</title><author>O'Donnell, Peter H. ; Arkenau, Hendrick Tobias ; Sridhar, Srikala S. ; Ong, Michael ; Drakaki, Alexandra ; Spira, Alexander I. ; Zhang, Jingsong ; Gordon, Michael S. ; Degboe, Arnold N. ; Gupta, Ashok K. ; Mukhopadhyay, Pralay ; Huang, Wenmei ; Abdullah, Shaad E. ; Angra, Natasha ; Roskos, Lorin K. ; Guo, Xiang ; Friedlander, Terence</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c3932-553a40160be27d4e47a65a682526da8e2bbcafd4c21da6e08ce2fea15cf22b043</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2020</creationdate><topic>Albumin</topic><topic>Biomarkers</topic><topic>Bladder</topic><topic>Bladder cancer</topic><topic>Cancer</topic><topic>Correlation analysis</topic><topic>durvalumab</topic><topic>Global health</topic><topic>health‐related quality of life</topic><topic>Immunotherapy</topic><topic>Inflammation</topic><topic>Lymphocytes</topic><topic>Metastases</topic><topic>Metastasis</topic><topic>Monoclonal antibodies</topic><topic>Oncology</topic><topic>Patients</topic><topic>patient‐reported outcome measures</topic><topic>Quality of life</topic><topic>Serum albumin</topic><topic>Shrinkage</topic><topic>Signs and symptoms</topic><topic>Targeted cancer therapy</topic><topic>tumor</topic><topic>Tumors</topic><topic>Urothelial carcinoma</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>O'Donnell, Peter H.</creatorcontrib><creatorcontrib>Arkenau, Hendrick Tobias</creatorcontrib><creatorcontrib>Sridhar, Srikala S.</creatorcontrib><creatorcontrib>Ong, Michael</creatorcontrib><creatorcontrib>Drakaki, Alexandra</creatorcontrib><creatorcontrib>Spira, Alexander I.</creatorcontrib><creatorcontrib>Zhang, Jingsong</creatorcontrib><creatorcontrib>Gordon, Michael S.</creatorcontrib><creatorcontrib>Degboe, Arnold N.</creatorcontrib><creatorcontrib>Gupta, Ashok K.</creatorcontrib><creatorcontrib>Mukhopadhyay, Pralay</creatorcontrib><creatorcontrib>Huang, Wenmei</creatorcontrib><creatorcontrib>Abdullah, Shaad E.</creatorcontrib><creatorcontrib>Angra, Natasha</creatorcontrib><creatorcontrib>Roskos, Lorin K.</creatorcontrib><creatorcontrib>Guo, Xiang</creatorcontrib><creatorcontrib>Friedlander, Terence</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>Oncogenes and Growth Factors Abstracts</collection><collection>Toxicology Abstracts</collection><collection>Environmental Sciences and Pollution Management</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Nursing & Allied Health Premium</collection><jtitle>Cancer</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>O'Donnell, Peter H.</au><au>Arkenau, Hendrick Tobias</au><au>Sridhar, Srikala S.</au><au>Ong, Michael</au><au>Drakaki, Alexandra</au><au>Spira, Alexander I.</au><au>Zhang, Jingsong</au><au>Gordon, Michael S.</au><au>Degboe, Arnold N.</au><au>Gupta, Ashok K.</au><au>Mukhopadhyay, Pralay</au><au>Huang, Wenmei</au><au>Abdullah, Shaad E.</au><au>Angra, Natasha</au><au>Roskos, Lorin K.</au><au>Guo, Xiang</au><au>Friedlander, Terence</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Patient‐reported outcomes and inflammatory biomarkers in patients with locally advanced/metastatic urothelial carcinoma treated with durvalumab in phase 1/2 dose‐escalation study 1108</atitle><jtitle>Cancer</jtitle><addtitle>Cancer</addtitle><date>2020-01-15</date><risdate>2020</risdate><volume>126</volume><issue>2</issue><spage>432</spage><epage>443</epage><pages>432-443</pages><issn>0008-543X</issn><eissn>1097-0142</eissn><abstract>Background
Durvalumab has shown meaningful clinical activity in patients with metastatic urothelial carcinoma (mUC) in Study 1108 (NCT01693562). An important focus in treatment is health‐related quality of life (HRQOL). Here, patient‐reported outcomes (PROs) from Study 1108 and their relationship with inflammatory biomarkers are explored.
Methods
Disease‐related symptoms, functioning, and HRQOL were assessed with the Functional Assessment of Cancer Therapy–Bladder (FACT‐Bl) and the European Organisation for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire Core 30 (QLQ‐C30). Relationships between PRO improvements and the best changes in the tumor size, albumin level, and neutrophil‐lymphocyte ratio (NLR) were assessed with Spearman correlation analysis.
Results
The mean FACT‐Bl total score improved from 107.5 (standard deviation [SD], 23.0) at the baseline to 115.4 (SD, 22.6) on day 113, with similar increases found for the Trial Outcome Index (TOI) and Bladder Cancer Subscale (BLCS) scores. The mean FACT‐Bl total scores improved over time, and the FACT‐Bl TOI scores significantly improved by day 113 (P < .05). The mean EORTC QLQ‐C30 Global Health Status/Quality of Life score improved from 57.1 (SD, 24.8) at the baseline to 69.0 (SD, 21.4) on day 113; the functional scale and symptom scores (day 113) were higher than the baseline scores (P < .05) for EORTC Social Functioning. The FACT‐Bl total, BLCS, and TOI scores improved in 32.6%, 34.9%, and 32.6% of the patients by day 113; 26.3% to 37.8% of the patients exhibited improvements in EORTC QLQ‐C30 functional scores. The best tumor shrinkage and posttreatment improvements in serum albumin and NLR correlated with increases in FACT‐Bl total, TOI, and BLCS scores and in EORTC Physical Functioning and Role Functioning scores (P < .05).
Conclusions
Durvalumab was associated with improvements in disease‐related symptoms, functioning, and HRQOL in patients with mUC. Improvements in systemic inflammation may contribute to PRO improvements in these patients.
In patients with locally advanced/metastatic urothelial carcinoma treated with durvalumab, improvements in patient‐reported outcomes correlate not only with objective tumor responses but also with reductions in markers of systemic inflammation. These findings provide insight into potential links between attenuation of inflammation in cancer and patient‐reported outcomes.</abstract><cop>United States</cop><pub>Wiley Subscription Services, Inc</pub><pmid>31581306</pmid><doi>10.1002/cncr.32532</doi><tpages>12</tpages><orcidid>https://orcid.org/0000-0003-2650-0049</orcidid><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0008-543X |
| ispartof | Cancer, 2020-01, Vol.126 (2), p.432-443 |
| issn | 0008-543X 1097-0142 |
| language | eng |
| recordid | cdi_proquest_journals_2334698916 |
| source | Wiley-Blackwell Journals; Wiley Online Library Free Content; Free E-Journal (出版社公開部分のみ）; Alma/SFX Local Collection |
| subjects | Albumin Biomarkers Bladder Bladder cancer Cancer Correlation analysis durvalumab Global health health‐related quality of life Immunotherapy Inflammation Lymphocytes Metastases Metastasis Monoclonal antibodies Oncology Patients patient‐reported outcome measures Quality of life Serum albumin Shrinkage Signs and symptoms Targeted cancer therapy tumor Tumors Urothelial carcinoma |
| title | Patient‐reported outcomes and inflammatory biomarkers in patients with locally advanced/metastatic urothelial carcinoma treated with durvalumab in phase 1/2 dose‐escalation study 1108 |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-14T15%3A10%3A30IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Patient%E2%80%90reported%20outcomes%20and%20inflammatory%20biomarkers%20in%20patients%20with%20locally%20advanced/metastatic%20urothelial%20carcinoma%20treated%20with%20durvalumab%20in%20phase%201/2%20dose%E2%80%90escalation%20study%201108&rft.jtitle=Cancer&rft.au=O'Donnell,%20Peter%20H.&rft.date=2020-01-15&rft.volume=126&rft.issue=2&rft.spage=432&rft.epage=443&rft.pages=432-443&rft.issn=0008-543X&rft.eissn=1097-0142&rft_id=info:doi/10.1002/cncr.32532&rft_dat=%3Cproquest_cross%3E2334698916%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2334698916&rft_id=info:pmid/31581306&rfr_iscdi=true |